Vaccine called AZD1222

Covid-19 vaccine trials reveals strong antibody and T-cell immune response for up to 56 days

Vaccine called AZD1222
Vaccine called AZD1222

Doses of Vaccine called AZD1222 were given to 1077 healthy adults between 18 and 55 in five UK hospitals in April and May as part of the phase one clinical trial for the vaccine being developed by AstraZeneca and Scientists at the University of Oxford. The results published in the Lancet Journal on Monday showed they induced strong antibody and T-cell immune responses for up to 56 days after they were given. T-cells are crucial for maintaining protection against the virus for years. Scientists found the response could be given even greater after a second dose of the vaccine. The report also said there were no serious adverse effects from the vaccine.